MINNEAPOLIS, MINNESOTA--(Marketwired - April 25, 2014) -
NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES
Further to its previously announced application to the TSX Venture Exchange, DiaMedica Inc. (TSX VENTURE:DMA) has received approval from the TSX Venture Exchange to amend 1,055,600 warrants (the "Warrants") of DiaMedica by extending the expiry date from May 8, 2014 to February 8, 2015. An amended and restated warrant indenture governing the Warrants has been filed concurrently herewith on SEDAR at www.sedar.com.
DiaMedica Inc. is a publicly traded (TSX VENTURE:DMA) clinical stage biopharmaceutical company focused on the discovery and development of novel therapies to treat diabetes and the complications associated with diabetes. DiaMedica's lead clinical stage compound, DM199, is a recombinant human protein known as rhKLK1 that represents a novel approach to treating diabetes and associated complications. DiaMedica is also developing a monoclonal antibody, DM204 for the treatment of Type 2 diabetes, which is in preclinical development.
DiaMedica is listed on the TSX Venture Exchange in Canada under the trading symbol 'DMA'.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of the contents of this News Release.